Cytopenia Clinical Trials

9 recruiting

Cytopenia Trials at a Glance

145 actively recruiting trials for cytopenia are listed on ClinicalTrialsFinder across 6 cities in 48 countries. The largest study group is Phase 2 with 62 trials, with the heaviest enrollment activity in Tianjin, Beijing, and Tianjin. Lead sponsors running cytopenia studies include Institute of Hematology & Blood Diseases Hospital, China, Peking University People's Hospital, and University Hospital, Bordeaux.

Treatments under study

About Cytopenia Clinical Trials

Looking for clinical trials for Cytopenia? There are currently 9 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Cytopenia trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Cytopenia clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 145 trials

Recruiting
Phase 2

Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models

Idiopathic CD4-PositiveT-Lymphocytopenia
National Institute of Allergy and Infectious Diseases (NIAID)40 enrolled1 locationNCT02015013
Recruiting
Phase 3

Study to Evaluate the Efficacy and Safety of Oral Rilzabrutinib in Adults With Immune Thrombocytopenia (ITP) Who Failed First-line Treatment

Immune Thrombocytopenia
Sanofi60 enrolled24 locationsNCT07007962
Recruiting
Phase 3

A Study to Assess the Efficacy and Safety of Efgartigimod IV in Adult Participants With Primary Immune Thrombocytopenia

Primary Immune Thrombocytopenia (ITP)
argenx69 enrolled94 locationsNCT06544499
Recruiting

Etiology, Pathogenesis, and Natural History of Idiopathic CD4+ Lymphocytopenia

Cryptococcal MeningitisWartsIdiopathic CD4+ Lymphocytopenia
National Institute of Allergy and Infectious Diseases (NIAID)950 enrolled1 locationNCT00867269
Recruiting
Phase 3

A Study to Evaluate the Efficacy and Safety of Hetrombopag Olamine Tablets Vs Placebo in Patients With Chemotherapy-Induced Thrombocytopenia

Patients With Chemotherapy-Induced Thrombocytopenia
Jiangsu HengRui Medicine Co., Ltd.150 enrolled7 locationsNCT07286032
Recruiting
Phase 4

Eltrombopag Combining Rituximab Versus Eltrombopag in the Management of Primary Immune Thrombocytopenia (ITP) in Adults

Primary Immune Thrombocytopenia (ITP)
Institute of Hematology & Blood Diseases Hospital, China224 enrolled1 locationNCT04518475
Recruiting
Phase 3

High-Dose Dexamethasone Combined With Orelabrutinib Versus High-Dose Dexamethasone Combined With Placebo in Adult Patients With Newly Diagnosed Primary Immune Thrombocytopenia

Primary Immune Thrombocytopenia (ITP)
Shandong University86 enrolled1 locationNCT07559331
Recruiting
Phase 1Phase 2

JAK1/2 Inhibitor Ruxolitinib for Relapsed/Refractory Immune Bone Marrow Failure

Severe Aplastic AnemiaSingle Lineage Cytopenias, T-LGLHypoplastic MDS
National Heart, Lung, and Blood Institute (NHLBI)145 enrolled1 locationNCT05998408
Recruiting
Early Phase 1

Early Intervention in High Risk CCUS

Clonal Cytopenia of Undetermined SignificanceCytopenia
Lachelle D. Weeks, MD, PhD108 enrolled1 locationNCT06802146
Recruiting
Phase 2Phase 3

A Study of Efgartigimod IV in Participants From 12 Years to Less Than 18 Years of Age With Chronic Immune Thrombocytopenia (ITP)

Immune Thrombocytopenic PurpuraITPITP - Immune Thrombocytopenia+1 more
argenx24 enrolled8 locationsNCT07194850
Recruiting
Phase 1Phase 2

A Study of Pirtobrutinib in Participants With Immune Thrombocytopenia

Immune Thrombocytopenia (ITP)
Eli Lilly and Company58 enrolled45 locationsNCT06721013
Recruiting

Clonal Hematopoiesis and Therapy-Emergent Myeloid Neoplasms in Patients With Cancers, CHANCES Study

Ovarian CarcinomaRecurrent Ovarian CarcinomaRecurrent Malignant Solid Neoplasm+7 more
University of Washington2,000 enrolled1 locationNCT06295965
Recruiting
Phase 2

Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia

Chronic Myelomonocytic LeukemiaRecurrent LymphomaRecurrent Diffuse Large B-Cell Lymphoma+5 more
Mayo Clinic80 enrolled4 locationsNCT03418038
Recruiting

Comparative Outcomes of PCC and Recombinant Activated Factor VIIa in Trauma-Associated Massive Transfusion

TraumaThromboembolusMassive Blood Transfusion; Thrombocytopenia
Zeliha Alicikus4 enrolled2 locationsNCT07290634
Recruiting
Phase 2

Study to Assess the Safety and Tolerability of Tafasitamab in Adult Participants With Primary Autoimmune Blood Cell Disorders

Immune Thrombocytopenia
Incyte Corporation56 enrolled40 locationsNCT07104565
Recruiting
Early Phase 1

Apixaban in Thrombocytopenia

ThrombocytopeniaDeep Vein ThrombosisPulmonary Embolism and Thrombosis+1 more
Rushad Patell30 enrolled1 locationNCT06886516
Recruiting
Phase 3

A Study of Nipocalimab or Intravenous Immunoglobulin (IVIG) in Pregnancies At Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)

Thrombocytopenia, Neonatal Alloimmune
Janssen Research & Development, LLC50 enrolled24 locationsNCT06533098
Recruiting
Phase 3

A Study on the Treatment of CTIT of the Efficacy and Safety With Romiplostim N01 Compared to Recombinant Human Interleukin-11

CTIT: Cancer Therapy Induced Thrombocytopenia
The First Affiliated Hospital with Nanjing Medical University88 enrolled1 locationNCT06759636
Recruiting
Phase 3

A Study of Nipocalimab in Reducing the Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)

Thrombocytopenia, Neonatal Alloimmune
Janssen Research & Development, LLC39 enrolled21 locationsNCT06449651
Recruiting
Phase 3

An Open-label Study of Intravenous Immunoglobulin (5%) for the Treatment of Primary Immune Thrombocytopenia

Primary Immune Thrombocytopenia (ITP)
Grand Shuyang Life Sciences (Chengdu) Co., Ltd.36 enrolled9 locationsNCT07233213